Floatz logo

Foritinib Succinate

SAF-189s

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Phase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the SAF-189s cohort.

Asset / SponsorPhaseRating
Crizotinib
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3B

Same molecule, other indications

Foritinib Succinate is also rated in:

ALK-positiveDormant
B
Indicative ·
60 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →